Advertisement

Topics

Pfizer gains Japanese approval for infliximab biosimilar

05:10 EDT 13 Jul 2018 | Generics and Biosimilars Initiative

Pfizer Japan announced on 2 July 2018 that it had gained Japanese approval for its infliximab biosimilar.

Original Article: Pfizer gains Japanese approval for infliximab biosimilar

NEXT ARTICLE

More From BioPortfolio on "Pfizer gains Japanese approval for infliximab biosimilar"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...